Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelLBxHealthANPCF 3-Year EBITDA Growth Rate is 23.80% as of Jun. 2026. The stock has 5 warning signs investors should review. Among 166 Medical Diagnostics & Research companies, CelLBxHealth ranks better than 68.07% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CelLBxHealth was 32.00% per year. The lowest was -77.80% per year. And the median was -3.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CelLBxHealth 3-Year EBITDA Growth Rate Related Terms
ANPCF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, CelLBxHealth's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CelLBxHealth 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CelLBxHealth's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.80% mean?
CelLBxHealth (ANPCF) has a 3-Year EBITDA Growth Rate of 23.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CelLBxHealth and its competitors. According to the industry distribution chart, CelLBxHealth ranks #53 out of 166 companies in the Medical Diagnostics & Research industry, placing it in the top 31.9%.
Is CelLBxHealth's 3-Year EBITDA Growth Rate too high?
CelLBxHealth's current 3-Year EBITDA Growth Rate is 23.80%. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 10.80. CelLBxHealth's value of 23.80% is 120.4% above this industry median. Based on the distribution chart, CelLBxHealth ranks #53 out of 166 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does CelLBxHealth's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, CelLBxHealth ranks #53 out of 166 companies for 3-Year EBITDA Growth Rate. This puts CelLBxHealth in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.80. CelLBxHealth's value of 23.80% is 120.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.80, based on 166 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CelLBxHealth's current 3-Year EBITDA Growth Rate of 23.80% is 120.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CelLBxHealth and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CelLBxHealth's current 3-Year EBITDA Growth Rate is 23.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (ANPCF) has a current 3-Year EBITDA Growth Rate of 23.80%. The current 3-Year EBITDA Growth Rate is 23.80% and 120.4% above the Medical Diagnostics & Research industry median of 10.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CelLBxHealth (ANPCF), the current 3-Year EBITDA Growth Rate is 23.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANPCF has been successfully added to your 
